Comparing Employer-Sponsored And Federal Exchange Plans: Wide Variations In Cost Sharing For Prescription Drugs

被引:15
作者
Buttorff, Christine [1 ]
Andersen, Martin S. [2 ]
Riggs, Kevin R. [3 ]
Alexander, G. Caleb [4 ]
机构
[1] RAND Corp, Arlington, VA 22202 USA
[2] Univ N Carolina, Dept Econ, Greensboro, NC 27412 USA
[3] Johns Hopkins Univ, Sch Med, Div Gen Internal Med, Baltimore, MD USA
[4] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA
关键词
D O I
10.1377/hlthaff.2014.0615
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Just under seven million Americans acquired private insurance through the new health insurance exchanges, or Marketplaces, in 2014. The exchange plans are required to cover essential health benefits, including prescription drugs. However, the generosity of prescription drug coverage in the plans has not been well described. Our primary objective was to examine the variability in drug coverage in the exchanges across plan types (health maintenance organization or preferred provider organization) and metal tiers (bronze, silver, gold, and platinum). Our secondary objective was to compare the exchange coverage to employer-sponsored coverage. Analyzing prescription drug benefit design data for the federally facilitated exchanges, we found wide variation in enrollees' out-of-pocket costs for generic, preferred brand-name, nonpreferred brand-name, and specialty drugs, not only across metal tiers but also within those tiers across plan types. Compared to employer-sponsored plans, exchange plans generally had lower premiums but provided less generous drug coverage. However, for low-income enrollees who are eligible for cost-sharing subsidies, the exchange plans may be more comparable to employer-based coverage. Policies and programs to assist consumers in matching their prescription drug needs with a plan's benefit design may improve the financial protection for the newly insured.
引用
收藏
页码:467 / 476
页数:10
相关论文
共 14 条
[1]   Cost per Treated Patient for Etanercept, Adalimumab, and Infliximab Across Adult Indications: a Claims Analysis [J].
Bonafede, Machaon M. K. ;
Gandra, Shravanthi R. ;
Watson, Crystal ;
Princic, Nicole ;
Fox, Kathleen M. .
ADVANCES IN THERAPY, 2012, 29 (03) :234-248
[2]  
Buntin MB, 2011, AM J MANAG CARE, V17, P222
[3]  
Census Bureau, AMERICAN FACTFINDER
[4]  
CMS. gov, THE CENTER FOR CONSU
[5]  
Collins SR, 2014, TOO HIGH A PRICE OUT
[6]  
Corlette S., 2013, WHAT STATES ARE DOIN
[7]  
Data. HealthCare. gov, QHP LANDSCAPE INDIVI
[8]  
Department of Health and Human Services Office of the Assistant Secretary for Planning and Evaluation, 2014, PROFILES OF AFFORDAB
[9]  
Henry J., 2012, EMPLOYER HEALTH BENE
[10]  
Holahan J, 2014, THE LAUNCH OF THE AF